Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 4
2004 4
2005 8
2006 13
2007 8
2008 7
2009 3
2010 5
2011 1
2012 3
2013 2
2014 3
2015 3
2016 8
2017 5
2018 7
2019 4
2020 6
2021 6
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

97 results

Results by year

Filters applied: . Clear all
Page 1
DNDI-6174 is a preclinical candidate for visceral leishmaniasis that targets the cytochrome bc1.
Braillard S, Keenan M, Breese KJ, Heppell J, Abbott M, Islam R, Shackleford DM, Katneni K, Crighton E, Chen G, Patil R, Lee G, White KL, Carvalho S, Wall RJ, Chemi G, Zuccotto F, González S, Marco M, Deakyne J, Standing D, Brunori G, Lyon JJ, Castañeda-Casado P, Camino I, Martinez Martinez MS, Zulfiqar B, Avery VM, Feijens PB, Van Pelt N, Matheeussen A, Hendrickx S, Maes L, Caljon G, Yardley V, Wyllie S, Charman SA, Chatelain E. Braillard S, et al. Among authors: yardley v. Sci Transl Med. 2023 Dec 13;15(726):eadh9902. doi: 10.1126/scitranslmed.adh9902. Epub 2023 Dec 13. Sci Transl Med. 2023. PMID: 38091406 Free PMC article.
Favorable Preclinical Pharmacological Profile of a Novel Antimalarial Pyrrolizidinylmethyl Derivative of 4-amino-7-chloroquinoline with Potent In Vitro and In Vivo Activities.
Basilico N, Parapini S, D'Alessandro S, Misiano P, Romeo S, Dondio G, Yardley V, Vivas L, Nasser S, Rénia L, Russell BM, Suwanarusk R, Nosten F, Sparatore A, Taramelli D. Basilico N, et al. Among authors: yardley v. Biomolecules. 2023 May 14;13(5):836. doi: 10.3390/biom13050836. Biomolecules. 2023. PMID: 37238706 Free PMC article.
Efficacy of oleylphosphocholine in experimental cutaneous leishmaniasis.
Van Bocxlaer K, Dixon J, Platteeuw JJ, Van Den Heuvel D, Mcarthur KN, Harris A, Alavijeh M, Croft SL, Yardley V. Van Bocxlaer K, et al. Among authors: yardley v. J Antimicrob Chemother. 2023 Jul 5;78(7):1723-1731. doi: 10.1093/jac/dkad162. J Antimicrob Chemother. 2023. PMID: 37229566 Free PMC article.
DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral Leishmaniasis.
Mowbray CE, Braillard S, Glossop PA, Whitlock GA, Jacobs RT, Speake J, Pandi B, Nare B, Maes L, Yardley V, Freund Y, Wall RJ, Carvalho S, Bello D, Van den Kerkhof M, Caljon G, Gilbert IH, Corpas-Lopez V, Lukac I, Patterson S, Zuccotto F, Wyllie S. Mowbray CE, et al. Among authors: yardley v. J Med Chem. 2021 Nov 11;64(21):16159-16176. doi: 10.1021/acs.jmedchem.1c01437. Epub 2021 Oct 28. J Med Chem. 2021. PMID: 34711050 Free PMC article.
Drug reformulation for a neglected disease. The NANOHAT project to develop a safer more effective sleeping sickness drug.
Sanderson L, da Silva M, Sekhar GN, Brown RC, Burrell-Saward H, Fidanboylu M, Liu B, Dailey LA, Dreiss CA, Lorenz C, Christie M, Persaud SJ, Yardley V, Croft SL, Valero M, Thomas SA. Sanderson L, et al. Among authors: yardley v. PLoS Negl Trop Dis. 2021 Apr 15;15(4):e0009276. doi: 10.1371/journal.pntd.0009276. eCollection 2021 Apr. PLoS Negl Trop Dis. 2021. PMID: 33857146 Free PMC article.
Novel Linker Variants of Antileishmanial/Antitubercular 7-Substituted 2-Nitroimidazooxazines Offer Enhanced Solubility.
Thompson AM, O'Connor PD, Yardley V, Maes L, Launay D, Braillard S, Chatelain E, Wan B, Franzblau SG, Ma Z, Cooper CB, Denny WA. Thompson AM, et al. Among authors: yardley v. ACS Med Chem Lett. 2021 Jan 21;12(2):275-281. doi: 10.1021/acsmedchemlett.0c00649. eCollection 2021 Feb 11. ACS Med Chem Lett. 2021. PMID: 33603975 Free PMC article.
Heteroaryl ether analogues of an antileishmanial 7-substituted 2-nitroimidazooxazine lead afford attenuated hERG risk: In vitro and in vivo appraisal.
Thompson AM, O'Connor PD, Marshall AJ, Yardley V, Maes L, Gupta S, Launay D, Braillard S, Chatelain E, Wan B, Franzblau SG, Ma Z, Cooper CB, Denny WA. Thompson AM, et al. Among authors: yardley v. Eur J Med Chem. 2021 Jan 1;209:112914. doi: 10.1016/j.ejmech.2020.112914. Epub 2020 Oct 10. Eur J Med Chem. 2021. PMID: 33268145
97 results